allergy

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedemain Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

June 14, 2025 10:48 ET  | Source: Celldex Therapeutics, Inc. 77% of patients (150 mg Q4W) treated with barzolvolimab who…

3 weeks ago

Reacta Healthcare announces transformation into a facility for multi-allergen manufacturing

1st production of pharmaceutical grade egg and milk challenge mealsProduct portfolio of challenge meals now includes peanut, milk and eggInnovation…

3 weeks ago

Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development

June 02, 2025 04:00 ET  | Source: Aravax MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) --…

1 month ago